Macrophage Pharma Ltd logo

Macrophage Pharma Ltd

Macrophage Pharma is an immuno-oncology company focussed on the discovery and development of novel therapies designed to enhance anti-tumour immune responses. Macrophage Pharma is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses. The Companys technology platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner to activate the bodys natural immune system to fight cancer.

Macrophage Pharma was founded by the CRT Pioneer Fund (ÇCPF) to discover and develop novel therapies designed to enhance anti-tumour immune responses.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.macrophagepharma.com
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Gainsborough House, 59-60 Thames Street, SL4 1TX
Berkshire
United Kingdom
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/macrophage-pharma” connections=”true” suffix=””]

Macrophage acquired global rights to a novel technology platform, Esterase Sensitive Motif (ESM), from Chroma Therapeutics Limited (Oxford, UK) together with discovery stage therapeutic assets. ESM technology platform delivers small molecule drugs to tumour associated macrophages in a highly selective manner, thus activating the bodys natural immune system to fight cancer. The platform has the ability to provide next-generation immunotherapies for a number of different cancers.

In Jan 2017, Macrophage Pharma raised £9 Mn in a Series A equity financing round led by CRT Pioneer Fund (ÇCPF) and joined by Novo Seeds, part of Novo A/S, and Aglaia Biomedical Ventures. The proceeds of the financing round will enable the Company to complete the preclinical development of its lead development candidate, a p38MAP kinase inhibitor, and advance two additional discovery candidates into pre-clinical development.